Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan-Reference-Cited by-同舟云学术

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Published:2023-02-05 Issue:2 Volume:33 Page:110-111
ISSN:0917-5040
Container-title:Journal of Epidemiology
language:en
Short-container-title:Journal of Epidemiology

Author:

Matsumoto Naomi¹^ORCID,Shimizu Junya²,Yokoyama Yuji³,Tsukahara Hirokazu⁴,Yorifuji Takashi¹^ORCID

Affiliation:

1. Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

2. Department of Pediatrics, National Hospital Organization, Okayama Medical Center

3. Department of Pediatrics, Okayama Aiiku Clinic

4. Department of Pediatrics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

Publisher

Japan Epidemiological Association

Subject

General Medicine,Epidemiology

Link

https://www.jstage.jst.go.jp/article/jea/33/2/33_JE20220265/_pdf

Reference6 articles.

1. 1. About COVID-19 Vaccination | Prime Minister’s Office of Japan n.d. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (accessed September 15, 2022).

2. 2. Hause AM. Safety monitoring of COVID-19 vaccine among children and young adults in v-safe Advisory Committee on Immunization Practices 2021.

3. 3. Walter EB, Talaat KR, Sabharwal C, et al; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46.

4. 4. Interim Report on Health Status Survey after Primary Series of Pfizer Vaccines in Children Aged 5–11 Years (2) p.62–83. https://www.mhlw.go.jp/content/10601000/000984400.pdf.

5. 5. Matsumoto N, Higuchi C, Mitsuhashi T, Hagiya H, Takao S, Yorifuji T. Report on adverse reactions to novel coronavirus vaccines. J Okayama Med Assoc. 2022;134:35–42 (in Japanese).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity;Heliyon;2024-08

2. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study;Journal of Infection and Chemotherapy;2024-08

3. Adverse reactions in young children receiving the coronavirus disease 2019 vaccine;Pediatrics International;2023-01